乙型肝炎肝硬化患者血清sICAM-1、IL-18测定及临床意义
摘要
目的探讨乙型肝炎肝硬化患者血清可溶性细胞间粘附分子-1(sICAM-1)、白细胞介素-18(IL-18)的变化及其临床意义。方法采用双抗体夹心酶联免疫吸附法(ELIAS)对60例乙型肝炎肝硬化患者和30例正常人血清sICAM-1、IL-18水平进行测定。对60例乙型肝炎肝硬化患者用ELISA法检测乙肝病毒学标志物、荧光定量PCR仪检测HBV-DNA含量、全自动生化分析仪检测肝功能(ALT、TBIL、ALB)、全自动血凝分析仪检测凝血酶原活动度(PTA)。结果(1)乙型肝炎肝硬化组患者血清sICAM-1水平明显高于健康对照组(P<0.01),肝硬化失代偿期组血清sICAM-1水平明显高于代偿期组(P<0.01)。乙型肝炎肝硬化组患者血清IL-18水平明显高于健康对照组(P<0.01),肝硬化失代偿期组血清IL-18水平明显高于代偿期组(P<0.01)。(2)乙型肝炎肝硬化患者Child C级组(C组)血清sICAM-1水平明显高于Child A级组(A组)、Child B级组(B组),B组高于A组,结果均有显著性差异(P<0.01)。乙型肝炎肝硬化患者C组血清IL-18水平明显高于A组、B组,B组高于A组,结果均有显著性差异(P<0.01)。(3)乙型肝炎肝硬化患者HBV-DNA阳性组血清sICAM-1水平与HBV-DNA阴性组相比较无显著性差异(P>0.05)。乙型肝炎肝硬化患者HBV-DNA阳性组血清IL-18水平与HBV-DNA阴性组相比较有显著性差异(P<0.01)。(4)乙型肝炎肝硬化患者血清sICAM-1水平与PTA、ALB呈显著负相关(r = -0.609、-0.373, P<0.01),与TBIL呈显著正相关(r = 0.635, P<0.01),与ALT无相关(r = 0.004, P>0.05)。乙型肝炎肝硬化患者血清IL-18水平与PTA、ALB呈显著负相关(r = -0.603、-0.392, P<0.01),与TBIL呈显著正相关(r = 0.591, P<0.01),与ALT无相关(r = 0.148, P>0.05)。血清sICAM-1水平与IL-18呈显著正相关(r = 0.432, P<0.01)。结论(1)sICAM-1、IL-18的高低在一定程度上反映肝细胞的损伤程度和肝硬化的严重程度,可为临床估计病情、判断预后、制定治疗方案提供参考指标。(2)sICAM-1水平变化与HBV的复制水平无关,继发性免疫反应导致sICAM-1表达,sICAM-1造成肝细胞损伤。IL-18水平变化与HBV复制活跃程度相关,临床上测定IL-18活性,在监测病毒复制状态及抗病毒治疗等方面都具有一定的实用价值。
Objective To investigate the changes of serum soluble intercellular adhesion molecule-1 (sICAM-1) and interleukin-18 (IL-18) and their clinical significance in patients with hepatitis B cirrhosis. Methods The serum level of sICAM-1 and IL-18 in 60 hepatitis B cirrhosis patients and 30 normal persons were detected by double antibody sandwich ELISA. The serum level of HBV-DNA was detected by fluorescence quantitative PCR instrument and HBV marker was detected by ELISA in 60 hepatitis B cirrhosis patients. Automatic biochemistry analyzer was used for measuring the serum level of liver function in 60 hepatitis B cirrhosis patients. Automated coagulation analyzer was used to measure the serum level of prothrombin activity (PTA) in 60 hepatitis B cirrhosis patients. Results (1) The serum level of sICAM-1 in patients with hepatitis B cirrhosis was significantly higher than that in normal persons (P<0.01), the serum level of sICAM-1 in decompensated cirrhosis group was obviously higher than that in compensated cirrhosis group (P<0.01). The serum level of IL-18 in patients with hepatitis B cirrhosis was significantly higher than that in normal persons (P<0.01), the serum level of IL-18 in decompensated cirrhosis group was obviously higher than that in compensated cirrhosis group (P<0.01). (2) The mean level of serum sICAM-1 in Child-Pugh C cirrhosis group (group C) was significantly higher than that in Child-Pugh A cirrhosis group (group A) and Child-Pugh B cirrhosis group (group B), the mean level of serum sICAM-1 in group B was higher than that in group A, the results were significantly different (P<0.01). The mean level of serum IL-18 in group C was significantly higher than that in group A and group B, the mean level of serum IL-18 in group B was higher than that in group A, the results were significantly different (P<0.01). (3) There was no significant difference between the serum sICAM-1 level of the hepatitis B cirrhosis patients with HBV-DNA positive group and HBV-DNA negative group (P>0.05). There was significant difference between the serum IL-18 level of the hepatitis B cirrhosis patients with HBV-DNA positive group and HBV-DNA negative group (P<0.01). (4) The serum sICAM-1 level in patients with hepatitis B cirrhosis had a negative correlation with PTA (r = -0.609, P<0.01) and albumin (ALB) (r = -0.373, P<0.01), a positive correlation with total bilirubin (TBIL) (r = 0.635, P<0.01), no correlation with alanine aminotransferase (ALT) (r = 0.004, P>0.05). The serum IL-18 level in patients with hepatitis B cirrhosis had a negative correlation with PTA (r = -0.603, P<0.01) and ALB (r = -0.392, P<0.01), a positive correlation with TBIL (r = 0.591, P<0.01), no correlation with ALT (r = 0.148, P>0.05). The serum sICAM-1 level had a positive correlation with IL-18 (r = 0.432, P<0.01). Conclusions (1) The level of sICAM-1 and IL-18 reflected the degree of hepatocyte damage and the severity of hepatitis B cirrhosis, and can provide reference indicator to evaluate the state of an illness, judge the prognosis and establish the remedial project for clinic. (2) The change of serum level of sICAM-1 in patients with hepatitis B cirrhosis was not related to the replication of HBV, it suggested that secondary immune injury lead to expression of sICAM-1, which promoted the injury of liver. The change of serum level of IL-18 in patients with hepatitis B cirrhosis was related to the replication of HBV, it has some practical use in monitoring HBV replication and antiviral therapy by measuring the level of IL-18.
Objective To investigate the changes of serum soluble intercellular adhesion molecule-1 (sICAM-1) and interleukin-18 (IL-18) and their clinical significance in patients with hepatitis B cirrhosis. Methods The serum level of sICAM-1 and IL-18 in 60 hepatitis B cirrhosis patients and 30 normal persons were detected by double antibody sandwich ELISA. The serum level of HBV-DNA was detected by fluorescence quantitative PCR instrument and HBV marker was detected by ELISA in 60 hepatitis B cirrhosis patients. Automatic biochemistry analyzer was used for measuring the serum level of liver function in 60 hepatitis B cirrhosis patients. Automated coagulation analyzer was used to measure the serum level of prothrombin activity (PTA) in 60 hepatitis B cirrhosis patients. Results (1) The serum level of sICAM-1 in patients with hepatitis B cirrhosis was significantly higher than that in normal persons (P<0.01), the serum level of sICAM-1 in decompensated cirrhosis group was obviously higher than that in compensated cirrhosis group (P<0.01). The serum level of IL-18 in patients with hepatitis B cirrhosis was significantly higher than that in normal persons (P<0.01), the serum level of IL-18 in decompensated cirrhosis group was obviously higher than that in compensated cirrhosis group (P<0.01). (2) The mean level of serum sICAM-1 in Child-Pugh C cirrhosis group (group C) was significantly higher than that in Child-Pugh A cirrhosis group (group A) and Child-Pugh B cirrhosis group (group B), the mean level of serum sICAM-1 in group B was higher than that in group A, the results were significantly different (P<0.01). The mean level of serum IL-18 in group C was significantly higher than that in group A and group B, the mean level of serum IL-18 in group B was higher than that in group A, the results were significantly different (P<0.01). (3) There was no significant difference between the serum sICAM-1 level of the hepatitis B cirrhosis patients with HBV-DNA positive group and HBV-DNA negative group (P>0.05). There was significant difference between the serum IL-18 level of the hepatitis B cirrhosis patients with HBV-DNA positive group and HBV-DNA negative group (P<0.01). (4) The serum sICAM-1 level in patients with hepatitis B cirrhosis had a negative correlation with PTA (r = -0.609, P<0.01) and albumin (ALB) (r = -0.373, P<0.01), a positive correlation with total bilirubin (TBIL) (r = 0.635, P<0.01), no correlation with alanine aminotransferase (ALT) (r = 0.004, P>0.05). The serum IL-18 level in patients with hepatitis B cirrhosis had a negative correlation with PTA (r = -0.603, P<0.01) and ALB (r = -0.392, P<0.01), a positive correlation with TBIL (r = 0.591, P<0.01), no correlation with ALT (r = 0.148, P>0.05). The serum sICAM-1 level had a positive correlation with IL-18 (r = 0.432, P<0.01). Conclusions (1) The level of sICAM-1 and IL-18 reflected the degree of hepatocyte damage and the severity of hepatitis B cirrhosis, and can provide reference indicator to evaluate the state of an illness, judge the prognosis and establish the remedial project for clinic. (2) The change of serum level of sICAM-1 in patients with hepatitis B cirrhosis was not related to the replication of HBV, it suggested that secondary immune injury lead to expression of sICAM-1, which promoted the injury of liver. The change of serum level of IL-18 in patients with hepatitis B cirrhosis was related to the replication of HBV, it has some practical use in monitoring HBV replication and antiviral therapy by measuring the level of IL-18.
引文
[1]中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志, 2005, 13 (12) : 881-891.
[2] Tsutsui H, Matsui K, Okamura H, et al. PathoPhysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev , 2000, 174: 194-209.
[3] Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol, 1997, 32 (5) : 401-10.
[4] Becker JC, Termeer C, Schmidt RE, et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interation. J Immunol, 1993, 151 (12) : 7224-7232.
[5] Satoh S, Nussler AK, Liu ZZ, et al. Proinflammatory cytokines and endotoxin stimulate ICAM-1 gene expression and secretion by normal human hepatocytes. Immunology, 1994, 82 (4) : 571-576.
[6] Nakanuma Y, Yasoshima M, Tsuneyamak, et al. Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Semin liver Dis, 1997, 17 (1) : 35-47.
[7] Nejjari M, Couvelard A, Mosnier JF, et al. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol, 2001, 195 (4) : 473-481.
[8]陆伦根,曾民德.免疫球蛋白超家族细胞粘附分子在慢性肝病中的作用.中华肝脏病杂志, 1998, 6 (2) : 126-128.
[9] Fabris C, pirisi M, Falleti E, el al. Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic 1iver disease. Clin Biochem, 1994, 27 (5) : 407-412.
[10] Bruno CM, Sciacca C, Cilio D, et al. Circulating adhesion molecules in patients withvirus-related chronic diseases of the liver. World J Gastroenterol, 2005, 11 (29) : 4566-4569.
[11] Thomson AW, Satoh S, Nussler AK, et al. Circulating intercellular adhesion molecule-l (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin Exp Immunol, 1994, 95 (1) : 83-90.
[12] Montalto G, Giannitrapani L, Soresi M, et al. Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interferon treatment. Intervirology, 2003, 46 (1) : 35-42.
[13]穆会君,顾静雄,张建中.病毒性肝炎肝纤维化患者血浆的细胞间粘附分子-1测定及其临床意义.临床检验杂志, 2001, 19 (1) : 31-32.
[14] Magness ST, Bataller R, Yang L, et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology, 2004, 40 (5) : 1151-1159.
[15]王伯良,刘勇,付国强,等.肝硬化患者血浆ET-1、NO和黏附分子的水平变化及临床意义.临床消化病杂志, 2007, 19 (5) : 301-303.
[16]李东复,太京华,潘留兰,等.慢性肝病患者血清sICAM-1与TGF-β1水平及临床意义.中国免疫学杂志, 2001, 17 (12) : 673-675.
[17]薛云平,邬小平,杨文龙,等.慢性乙型重型肝炎患者血清sICAM-1的检测及临床意义.实用肝脏病杂志, 2007, 10 (5) : 298-300.
[18]蒋业贵,李兆申.白细胞介素-18在肝损害中的作用与机制.肝脏, 2003, 8 (1) : 49-50.
[19] Hanck C, Manigold T, Bocker U, et al. Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut, 2001, 49 (1) : 106-111.
[20] Yamano T, Higashi T, Nouso K, et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol, 2000, 122 (2) : 227-231.
[21] Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the Pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol, 2002, 160 (20) : 641-654.
[22] McGuinness PH, Painter D, Davies S, et al. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46 (2) : 260-269.
[23]丁世华,刘俊.肝炎肝硬化患者血清IL-10、IL-18水平的变化及意义.江西医学院学报, 2005, 45 (3) : 76-81.
[24]刘兰,刘佩芝,唐先梅.慢性乙型肝炎患者血清IL-18水平与HBVDNA含量的关系.胃肠病学和肝病学杂志, 2007, 16 (2) : 156-157.
[25] Tsui LV, Guidotti LG, Ishikawa T, et al. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T Iymphocyte-activated hepatocytes. Proc Natl Acad Sci USA, 1995, 92 (26) : 12398-12402.
[26] Matsumoto G, Sunamura M, Shimamura H, et al. Adjuvant immunotherapy using fibroblasts genetically engineered to secret interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Surgery, 1999, 125 (3) : 257-264.
[27]陈永胜,李东复,刘晓阳,等.乙型肝炎肝硬化患者HBV复制对外周血IL-12和IL-18表达水平的影响.吉林大学学报(医学版), 2008, 34 (6) : 1038-1041.
[28]潘红英. IL-18与肝损伤机理研究新进展.浙江医学, 2000, 22 (11) : 702-703.
[29] Sakamoto S, Okanoue T, Itoh Y, et al. Intercellular adhesion molecule-1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats. Hepatology, 1997, 26 (3) : 658-663.
[30]孙颖,陈焕永,王菲,等.白细胞介素-18对慢性乙型肝炎患者外周血单个核细胞的作用及意义.中华肝脏病杂志, 2003, 11 (8) : 470-473.
[1]陆伦根,曾民德.免疫球蛋白超家族细胞粘附分子在慢性肝病中的作用.中华肝脏病杂志, 1998, 6 (2) : 126-128.
[2] Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther, 1999, 6 (5) : 808-815.
[3] Ariel A , Novick D , Rubinstein M , et al . IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol, 2002, 72 (1) : 192-198.
[4] Sugawara I, Yamada H,Kaneko H, et al. Role of interleukin-18(IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun, 1999, 67 (5) : 2585-2589.
[5] Hodges JL , Ireland DD, Reiss CS. The role of interleukin-18 in vesicular stomatitis virus infection of the CNS. Viral Immunol, 2001, 14 (2) : 181-191.
[6] Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol, 1997, 32 (5) : 401-410.
[7]张海信,李红霞,郭文有,等.大肠癌中ICAM-1基因的表达及其对预后的影响.中国现代医药杂志, 2006, 8 (6) : 58-60.
[8] Becker JC, Termeer C, Schmidt RE, et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interation. J Immunol, 1993, 151 (12) : 7224-7232.
[9] Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol, 1991, 147 (11) : 3788-3793.
[10] Satoh S, Nussler AK, Liu ZZ et al. Proinflammatory cytokines and endotoxin stimulate ICAM-1 gene expression and secretion by normal human hepatocytes. Immunology, 1994 , 82 (4) : 571-576.
[11]尹洪竹,王清朝,刘金星.可溶性细胞间粘附分子-1与肝病关系研究进展.河北医药, 2000, 22 (6) : 469-470.
[12] Horiike N, Onji M, Kumon I, et al. Intercellular adhesion molecule-1 expression on the hepatocyte membrane of patients with chronic hepatitis B and C. Liver, 1993, 13 (1) : 10-14.
[13] Capra F, De Maria E, Lunardi C, et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment. J Infect Dis, 2000, 181 (2) : 425-431.
[14]徐人欢,王贵强,吕淑兰,等.可溶性细胞间粘附分子-1在病毒性肝炎患者血清中的检测及意义.中华传染病杂志, 2000, 18 (3) : 192-193.
[15] Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the liver. Hepatology, 1997, 25 (2) : 335-342.
[16]贾青青,王晓玲.慢性肝病患者血清可溶性细胞间粘附分子-1和透明质酸水平及其意义.临床消化病杂志, 2000, 12 (2) : 70-71.
[17]贺永文,朱传武,曾令兰,等.慢性病毒性肝炎与可溶性细胞间粘附分子-1关系的研究.中国实用内科杂志, 2000, 20 (2) : 92-93.
[18] Mickelson JK, Kukielka G, Bravenec JS, et al. Differential expression and releases of CD54 induced by cytokines. Hepatology, 1995, 22 (3) : 866-875.
[19]高永琳,林德馨,黄伟明,等.乙肝患者血清sICAM-1检测的临床意义.医学临床研究, 2003, 20 (1) : 13-15.
[20]薛云平,邬小平,杨文龙,等.慢性乙型重型肝炎患者血清sICAM-1的检测及临床意义.实用肝脏病杂志, 2007, 10 (5) : 298-300.
[21]穆会君,顾静雄,张建中.病毒性肝炎肝纤维化患者血浆的细胞间粘附分子-1测定及其临床意义.临床检验杂志, 2001, 19 (1) : 31-32.
[22]林德馨,高永琳,黄伟明等.可溶性细胞间粘附分子-1与乙型肝炎患者肝细胞损伤和肝纤维化关系的研究.医学临床研究, 2005, 22 (1) : 14-16.
[23] Hellerbrand C, Wang SC, Tsukamoto H, et al. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology, 1996, 24 (3) : 670-676.
[24] Horiike N, Onji M, Kumamoto I, et al. Soluble intercellular adhesion molecule-1 in serum in chronic hepatitis B and C. J Gastroenterol, 1994, 29 (4) : 455-458.
[25]谢世峰.肝炎后肝硬化患者血清可溶性细胞间粘附分子-1检测的临床意义.浙江实用医学, 2001, 6 (5) : 8-9.
[26]贾道全,郑雪莲,罗成福,等.肝炎后肝硬化患者细胞因子和粘附分子水平变化及其临床意义.中华消化杂志, 2003, 23 (10) : 630-631.
[27] Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 1995, 378 (6552) : 88-91.
[28] Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol, 1996, 156 (11) : 4274-4279.
[29] Debets R, Timans JC, Churakowa T, et al. IL-18 receptors,their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol, 2000, 165 (9) : 4950-4956.
[30] Jin M, Jung HJ, Choi JJ, et al. Activation of selective transcription factors and cytokines by water-soluble extract from Lentinus lepideus. Exp biol Med (Maywood), 2003, 228 (6) : 749-758.
[31] Reznikov LL, Kim SH, Westcott JY, et al. IL-18 binding protein increase spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci USA, 2000, 97 (5) : 2174-2179.
[32]蒋业贵,李兆申.白细胞介素-18在肝损害中的作用与机制.肝脏, 2003, 8 (1) : 49-50.
[33] Milich DR. Influence of T-helper cell subsets and crossregulation in hepatitis B virusinfection. J Viral Hepat, 1997, 4 Suppl 2 : 48-59.
[34] Yumoto E, Higashi T, Nouso K, et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol, 2002, 17 (3) : 285-294 .
[35]张萍,吴文漪.乙型病毒性肝炎患者血清中IL-18的检测及意义.中华肝脏病杂志, 2001, 9 (5) : 305.
[36] Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol, 2002, 22 (6) : 331-337.
[37]孔明武,王湖荣,任喜民,等.白细胞介素-18在慢性乙型肝炎发病机理中作用探讨.陕西医学杂志, 2001, 30 (6) : 323-325.
[38]刘家秀,史亚明,黄加忠,等.慢性乙肝患者血清sICAM-1与IL-18的变化及相关研究.临床肝胆病杂志, 2003, 19 (4) : 224-225.
[39] Malizia G, Dino 0, Pisa R, et al. Expression of leukocyte adhesion molecules in the liver of patients with chronic hepatitis B virus infection. Gastroenterology, 1991, 100 (3) : 749-755.
[40]刘兰,刘佩芝,唐先梅.慢性乙型肝炎患者血清IL-18水平与HBVDNA含量的关系.胃肠病学和肝病学杂志, 2007, 16 (2) : 156-157.
[41]文维群,章廉,肖红,等.乙型肝炎病毒感染者IL-18基因的转录及表达.中华医学杂志, 2001, 81 (11) : 655-658.
[42] McGuinness PH, Painter D, Davies S, et al. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46 (2) : 260-269.
[43]杨小云,观晓辉,曾宏,等.白细胞介素-18、γ-干扰素与慢性乙型肝炎肝纤维化临床与病理的关系.广东医药, 2007, 28 (8) : 1250-1251.
[44]曾宏.乙型肝炎失代偿期肝硬化患者血清内毒素、IL-12、IL-18水平的检测及其意义.广东医学院学报, 2005, 23 (3) : 264-265.
[45]唐宝璋,田庚善.白细胞介素18与病毒性肝炎.中华传染病杂志, 2005, 23 (3) : 212-214.
[46] Tsutsui H, Matsui K, Kawada N, et al. IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol, 1997, 159 (8) : 3961-3967.
[47] Matsui K, Yoshimoto T, Tsutsui H, et al. Propionibacterium acnes treatment diminishes CD4+NK1.1+T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol, 1997, 159 (1) : 97-106.
[48]陈永胜,李东复,刘晓阳,等.乙型肝炎肝硬化患者HBV复制对外周血IL-12和IL-18表达水平的影响.吉林大学学报(医学版), 2008, 34 (6) : 1038-1041.
[49]潘红英. IL-18与肝损伤机理研究新进展.浙江医学, 2000, 22 (11) : 702-703.
[2] Tsutsui H, Matsui K, Okamura H, et al. PathoPhysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev , 2000, 174: 194-209.
[3] Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol, 1997, 32 (5) : 401-10.
[4] Becker JC, Termeer C, Schmidt RE, et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interation. J Immunol, 1993, 151 (12) : 7224-7232.
[5] Satoh S, Nussler AK, Liu ZZ, et al. Proinflammatory cytokines and endotoxin stimulate ICAM-1 gene expression and secretion by normal human hepatocytes. Immunology, 1994, 82 (4) : 571-576.
[6] Nakanuma Y, Yasoshima M, Tsuneyamak, et al. Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Semin liver Dis, 1997, 17 (1) : 35-47.
[7] Nejjari M, Couvelard A, Mosnier JF, et al. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol, 2001, 195 (4) : 473-481.
[8]陆伦根,曾民德.免疫球蛋白超家族细胞粘附分子在慢性肝病中的作用.中华肝脏病杂志, 1998, 6 (2) : 126-128.
[9] Fabris C, pirisi M, Falleti E, el al. Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic 1iver disease. Clin Biochem, 1994, 27 (5) : 407-412.
[10] Bruno CM, Sciacca C, Cilio D, et al. Circulating adhesion molecules in patients withvirus-related chronic diseases of the liver. World J Gastroenterol, 2005, 11 (29) : 4566-4569.
[11] Thomson AW, Satoh S, Nussler AK, et al. Circulating intercellular adhesion molecule-l (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin Exp Immunol, 1994, 95 (1) : 83-90.
[12] Montalto G, Giannitrapani L, Soresi M, et al. Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interferon treatment. Intervirology, 2003, 46 (1) : 35-42.
[13]穆会君,顾静雄,张建中.病毒性肝炎肝纤维化患者血浆的细胞间粘附分子-1测定及其临床意义.临床检验杂志, 2001, 19 (1) : 31-32.
[14] Magness ST, Bataller R, Yang L, et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology, 2004, 40 (5) : 1151-1159.
[15]王伯良,刘勇,付国强,等.肝硬化患者血浆ET-1、NO和黏附分子的水平变化及临床意义.临床消化病杂志, 2007, 19 (5) : 301-303.
[16]李东复,太京华,潘留兰,等.慢性肝病患者血清sICAM-1与TGF-β1水平及临床意义.中国免疫学杂志, 2001, 17 (12) : 673-675.
[17]薛云平,邬小平,杨文龙,等.慢性乙型重型肝炎患者血清sICAM-1的检测及临床意义.实用肝脏病杂志, 2007, 10 (5) : 298-300.
[18]蒋业贵,李兆申.白细胞介素-18在肝损害中的作用与机制.肝脏, 2003, 8 (1) : 49-50.
[19] Hanck C, Manigold T, Bocker U, et al. Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut, 2001, 49 (1) : 106-111.
[20] Yamano T, Higashi T, Nouso K, et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol, 2000, 122 (2) : 227-231.
[21] Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the Pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol, 2002, 160 (20) : 641-654.
[22] McGuinness PH, Painter D, Davies S, et al. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46 (2) : 260-269.
[23]丁世华,刘俊.肝炎肝硬化患者血清IL-10、IL-18水平的变化及意义.江西医学院学报, 2005, 45 (3) : 76-81.
[24]刘兰,刘佩芝,唐先梅.慢性乙型肝炎患者血清IL-18水平与HBVDNA含量的关系.胃肠病学和肝病学杂志, 2007, 16 (2) : 156-157.
[25] Tsui LV, Guidotti LG, Ishikawa T, et al. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T Iymphocyte-activated hepatocytes. Proc Natl Acad Sci USA, 1995, 92 (26) : 12398-12402.
[26] Matsumoto G, Sunamura M, Shimamura H, et al. Adjuvant immunotherapy using fibroblasts genetically engineered to secret interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Surgery, 1999, 125 (3) : 257-264.
[27]陈永胜,李东复,刘晓阳,等.乙型肝炎肝硬化患者HBV复制对外周血IL-12和IL-18表达水平的影响.吉林大学学报(医学版), 2008, 34 (6) : 1038-1041.
[28]潘红英. IL-18与肝损伤机理研究新进展.浙江医学, 2000, 22 (11) : 702-703.
[29] Sakamoto S, Okanoue T, Itoh Y, et al. Intercellular adhesion molecule-1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats. Hepatology, 1997, 26 (3) : 658-663.
[30]孙颖,陈焕永,王菲,等.白细胞介素-18对慢性乙型肝炎患者外周血单个核细胞的作用及意义.中华肝脏病杂志, 2003, 11 (8) : 470-473.
[1]陆伦根,曾民德.免疫球蛋白超家族细胞粘附分子在慢性肝病中的作用.中华肝脏病杂志, 1998, 6 (2) : 126-128.
[2] Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther, 1999, 6 (5) : 808-815.
[3] Ariel A , Novick D , Rubinstein M , et al . IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol, 2002, 72 (1) : 192-198.
[4] Sugawara I, Yamada H,Kaneko H, et al. Role of interleukin-18(IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun, 1999, 67 (5) : 2585-2589.
[5] Hodges JL , Ireland DD, Reiss CS. The role of interleukin-18 in vesicular stomatitis virus infection of the CNS. Viral Immunol, 2001, 14 (2) : 181-191.
[6] Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol, 1997, 32 (5) : 401-410.
[7]张海信,李红霞,郭文有,等.大肠癌中ICAM-1基因的表达及其对预后的影响.中国现代医药杂志, 2006, 8 (6) : 58-60.
[8] Becker JC, Termeer C, Schmidt RE, et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interation. J Immunol, 1993, 151 (12) : 7224-7232.
[9] Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol, 1991, 147 (11) : 3788-3793.
[10] Satoh S, Nussler AK, Liu ZZ et al. Proinflammatory cytokines and endotoxin stimulate ICAM-1 gene expression and secretion by normal human hepatocytes. Immunology, 1994 , 82 (4) : 571-576.
[11]尹洪竹,王清朝,刘金星.可溶性细胞间粘附分子-1与肝病关系研究进展.河北医药, 2000, 22 (6) : 469-470.
[12] Horiike N, Onji M, Kumon I, et al. Intercellular adhesion molecule-1 expression on the hepatocyte membrane of patients with chronic hepatitis B and C. Liver, 1993, 13 (1) : 10-14.
[13] Capra F, De Maria E, Lunardi C, et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment. J Infect Dis, 2000, 181 (2) : 425-431.
[14]徐人欢,王贵强,吕淑兰,等.可溶性细胞间粘附分子-1在病毒性肝炎患者血清中的检测及意义.中华传染病杂志, 2000, 18 (3) : 192-193.
[15] Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the liver. Hepatology, 1997, 25 (2) : 335-342.
[16]贾青青,王晓玲.慢性肝病患者血清可溶性细胞间粘附分子-1和透明质酸水平及其意义.临床消化病杂志, 2000, 12 (2) : 70-71.
[17]贺永文,朱传武,曾令兰,等.慢性病毒性肝炎与可溶性细胞间粘附分子-1关系的研究.中国实用内科杂志, 2000, 20 (2) : 92-93.
[18] Mickelson JK, Kukielka G, Bravenec JS, et al. Differential expression and releases of CD54 induced by cytokines. Hepatology, 1995, 22 (3) : 866-875.
[19]高永琳,林德馨,黄伟明,等.乙肝患者血清sICAM-1检测的临床意义.医学临床研究, 2003, 20 (1) : 13-15.
[20]薛云平,邬小平,杨文龙,等.慢性乙型重型肝炎患者血清sICAM-1的检测及临床意义.实用肝脏病杂志, 2007, 10 (5) : 298-300.
[21]穆会君,顾静雄,张建中.病毒性肝炎肝纤维化患者血浆的细胞间粘附分子-1测定及其临床意义.临床检验杂志, 2001, 19 (1) : 31-32.
[22]林德馨,高永琳,黄伟明等.可溶性细胞间粘附分子-1与乙型肝炎患者肝细胞损伤和肝纤维化关系的研究.医学临床研究, 2005, 22 (1) : 14-16.
[23] Hellerbrand C, Wang SC, Tsukamoto H, et al. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology, 1996, 24 (3) : 670-676.
[24] Horiike N, Onji M, Kumamoto I, et al. Soluble intercellular adhesion molecule-1 in serum in chronic hepatitis B and C. J Gastroenterol, 1994, 29 (4) : 455-458.
[25]谢世峰.肝炎后肝硬化患者血清可溶性细胞间粘附分子-1检测的临床意义.浙江实用医学, 2001, 6 (5) : 8-9.
[26]贾道全,郑雪莲,罗成福,等.肝炎后肝硬化患者细胞因子和粘附分子水平变化及其临床意义.中华消化杂志, 2003, 23 (10) : 630-631.
[27] Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 1995, 378 (6552) : 88-91.
[28] Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol, 1996, 156 (11) : 4274-4279.
[29] Debets R, Timans JC, Churakowa T, et al. IL-18 receptors,their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol, 2000, 165 (9) : 4950-4956.
[30] Jin M, Jung HJ, Choi JJ, et al. Activation of selective transcription factors and cytokines by water-soluble extract from Lentinus lepideus. Exp biol Med (Maywood), 2003, 228 (6) : 749-758.
[31] Reznikov LL, Kim SH, Westcott JY, et al. IL-18 binding protein increase spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci USA, 2000, 97 (5) : 2174-2179.
[32]蒋业贵,李兆申.白细胞介素-18在肝损害中的作用与机制.肝脏, 2003, 8 (1) : 49-50.
[33] Milich DR. Influence of T-helper cell subsets and crossregulation in hepatitis B virusinfection. J Viral Hepat, 1997, 4 Suppl 2 : 48-59.
[34] Yumoto E, Higashi T, Nouso K, et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol, 2002, 17 (3) : 285-294 .
[35]张萍,吴文漪.乙型病毒性肝炎患者血清中IL-18的检测及意义.中华肝脏病杂志, 2001, 9 (5) : 305.
[36] Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol, 2002, 22 (6) : 331-337.
[37]孔明武,王湖荣,任喜民,等.白细胞介素-18在慢性乙型肝炎发病机理中作用探讨.陕西医学杂志, 2001, 30 (6) : 323-325.
[38]刘家秀,史亚明,黄加忠,等.慢性乙肝患者血清sICAM-1与IL-18的变化及相关研究.临床肝胆病杂志, 2003, 19 (4) : 224-225.
[39] Malizia G, Dino 0, Pisa R, et al. Expression of leukocyte adhesion molecules in the liver of patients with chronic hepatitis B virus infection. Gastroenterology, 1991, 100 (3) : 749-755.
[40]刘兰,刘佩芝,唐先梅.慢性乙型肝炎患者血清IL-18水平与HBVDNA含量的关系.胃肠病学和肝病学杂志, 2007, 16 (2) : 156-157.
[41]文维群,章廉,肖红,等.乙型肝炎病毒感染者IL-18基因的转录及表达.中华医学杂志, 2001, 81 (11) : 655-658.
[42] McGuinness PH, Painter D, Davies S, et al. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46 (2) : 260-269.
[43]杨小云,观晓辉,曾宏,等.白细胞介素-18、γ-干扰素与慢性乙型肝炎肝纤维化临床与病理的关系.广东医药, 2007, 28 (8) : 1250-1251.
[44]曾宏.乙型肝炎失代偿期肝硬化患者血清内毒素、IL-12、IL-18水平的检测及其意义.广东医学院学报, 2005, 23 (3) : 264-265.
[45]唐宝璋,田庚善.白细胞介素18与病毒性肝炎.中华传染病杂志, 2005, 23 (3) : 212-214.
[46] Tsutsui H, Matsui K, Kawada N, et al. IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol, 1997, 159 (8) : 3961-3967.
[47] Matsui K, Yoshimoto T, Tsutsui H, et al. Propionibacterium acnes treatment diminishes CD4+NK1.1+T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol, 1997, 159 (1) : 97-106.
[48]陈永胜,李东复,刘晓阳,等.乙型肝炎肝硬化患者HBV复制对外周血IL-12和IL-18表达水平的影响.吉林大学学报(医学版), 2008, 34 (6) : 1038-1041.
[49]潘红英. IL-18与肝损伤机理研究新进展.浙江医学, 2000, 22 (11) : 702-703.